MARKET

QTRX

QTRX

Quanterix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.41
-0.47
-1.07%
Opening 10:40 12/02 EST
OPEN
43.79
PREV CLOSE
43.88
HIGH
44.21
LOW
42.50
VOLUME
9.63K
TURNOVER
--
52 WEEK HIGH
52.75
52 WEEK LOW
10.90
MARKET CAP
1.37B
P/E (TTM)
-37.2011
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Quanterix names new operations chief
Quanterix (QTRX) names William Geist to COO post, effective November 16, 2020.Geist brings operational experience to the company as it scales to support rapid growth and commercial success.In his role, Geist will
Seekingalpha · 11/18 21:38
Quanterix Appoints William Geist as Chief Operating Officer
Quanterix Appoints William Geist as Chief Operating Officer
Business Wire · 11/18 21:28
Quanterix to Participate in the Canaccord Medical Technologies and Diagnostics Forum
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m., EST. Hrusovsky will also host virtual one-on-one and group meetings with institutional investors that day.
Business Wire · 11/13 17:36
Quanterix Corporation Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders will be ecstatic, with their stake up 34% over the past week following Quanterix Corporation's...
Simply Wall St. · 11/09 12:29
Quanterix: Still Bullish But Valuation Less Compelling
Abbot and NIH contract provides another validation point for the Quanterix platform and opportunity for revenue upside.Quanterix has performed well over the last two weeks and the valuation has become full in the near-term, but the company can still be a long-term hold for patient investors.My new price target of $50 translates to ~10% upside from here.
Seekingalpha · 10/13 15:35
Elanco Animal Health, 3D Systems: 5 Stock Gainers for Wednesday
Elanco Animal Health, Ocular Therapeutix, 3D Systems, Perion Networks and Quanterix are five of Wednesday's top stock gainers.
TheStreet.com · 10/07 19:12
Quanterix bags NIH RADx contract for Covid-19 antigen test
Quanterix (QTRX) enters into a Phase 2 contract with the National Institutes of Health through its Rapid Acceleration of Diagnostics or RADx℠ initiative.The contract has a total award value of $18.2M.It
Seekingalpha · 10/06 20:00
Quanterix Receives National Institutes of Health RADx Contract to Advance Antigen Test for SARS-CoV-2 (COVID-19)
Quanterix Receives National Institutes of Health RADx Contract to Advance Antigen Test for SARS-CoV-2 (COVID-19).
Business Wire · 10/06 19:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QTRX. Analyze the recent business situations of Quanterix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QTRX stock price target is 51.50 with a high estimate of 55.00 and a low estimate of 47.00.
EPS
Institutional Holdings
Institutions: 150
Institutional Holdings: 26.39M
% Owned: 83.33%
Shares Outstanding: 31.67M
TypeInstitutionsShares
Increased
47
2.14M
New
28
1.18M
Decreased
21
1.00M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.14%
Healthcare Equipment & Supplies
-0.27%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Hrusovsky
Chairman/President/Chief Executive Officer/Director
E. Kevin Hrusovsky
Chief Financial Officer
Amol Chaubal
Chief Operating Officer
William Geist
Senior Vice President/Chief Technology Officer
David Duffy
Senior Vice President
Dawn Mattoon
Senior Vice President
Mark Roskey
Independent Director
Douglas Cole
General Counsel/Secretary
John Fry
Lead Director/Independent Director
Martin Madaus
Independent Director
Keith Crandell
Independent Director
Marijn Dekkers
Independent Director
Sarah Hlavinka
Independent Director
Paul Meister
Independent Director
David Walt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About QTRX
Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Quanterix Corp stock information, including NASDAQ:QTRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QTRX stock methods without spending real money on the virtual paper trading platform.